Fibrogenesis and inflammatory bowel disease;Fibrogénesis y enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 30, Issue 1, 2007, Pages 36-41

  Sans, Miquel ^a,b   Masamunt, M Carmen ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15;

CELL FUNCTION; COLLAGEN SYNTHESIS; CROHN DISEASE; DISEASE COURSE; ENTERITIS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; GENETIC PREDISPOSITION; HUMAN; INTESTINAL FIBROSIS; INTESTINE STENOSIS; PREVALENCE; PROTEIN EXPRESSION; REVIEW;

EID: 33846908583     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13097449     Document Type: Article

References (38)

1. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
2. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:Suppl A:5-36.
3. Sicilia B, Vicente R, Arroyo MT, Arribas F, Gomollon F. Surgery at follow-up in an incidence cohort of patients with Crohn's disease in Aragon (Spain): etiology, type of surgery and associated epidemiological factors. Gastroenterol Hepatol. 2005;28:105-9.
4. Domenech E, Scala L, Bernal I, Garcia-Planella E, Casalots A, Pinol M, et al. Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study. Gastroenterol Hepatol. 2004;27:563-7.
5. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-82.
6. Álvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693-700.
7. Sarem M, Znaidak R, Macias M, Rey R. Hepatic stellate cells: it's role in normal and pathological conditions. Gastroenterol Hepatol. 2006;29:93-101.
8. García-Suárez C, Crespo J, Fernández-Gil PL, Amado JA, García-Unzueta MT, Pons Romero F. Plasma leptin levels in patients with primary biliary cirrhosis and their relationship with degree of fibrosis. Gastroenterol Hepatol. 2004;27:47-50.
9. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-88.
10. Radlmayr M, Torok HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology. 2002;122:2091-2.
11. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002;359:1661-5.
12. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99:2393-404.
13. Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol. 2006;101:99-106.
14. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology. 1988;94:257-65.
15. Matthes H, Herbst H, Schuppan D, Stallmach A, Milani S, Stein H, et al. Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. Gastroenterology. 1992;102:431-42.
16. Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut. 1999;45:210-7.
17. Koutroubakis IE, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis AN, et al. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol. 2003;56:817-20.
18. Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol. 1998;30:909-22.
19. Di Mola FF, Di Sebastiano P, Gardini A, Innocenti P, Zimmermann A, Buchler MW, et al. Differential expression of connective tissue growth factor in inflammatory bowel disease. Digestion. 2004;69:245-53.
20. Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7:16-26.
21. El Yafi F, Winkler R, Delvenne P, Boussif N, Belaiche J, Louis E. Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clin Exp Immunol. 2005;139:526-33.
22. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zimmermann EM, Sartor RB, et al. IGF-I and procollagen alpha 1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2000;279:1307G-22G.
23. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol. 1994;47:113-6.
24. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000;47:57-62.
25. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998;152:1005-14.
26. Musso A, Condon TP, West GA, De La Motte C, Strong SA, Levine AD, et al. Regulation of ICAM-1-mediated fibroblast-T cell reciprocal interaction: implications for modulation of gut inflammation. Gastroenterology. 1999;117:546-56.
27. Vogel JD, West GA, Danese S, De La Motte C, Phillips MH, Strong SA, et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology. 2004;126:63-80.
28. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:226-36.
29. Strong SA, Pizarro TT, Klein JS, Cominelli F, Fiocchi C. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology. 1998;114:1244-56.
30. Simmons JG, Pucilowska JB, Keku TO, Lund PK. IGF-1 and TGF-beta1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. Am J Physiol Gastrointest Liver Physiol. 2002;283:809G-18G.
31. Masur SK, Dewal HS, Dinh TT, Erenburg I, Petridou S. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci USA. 1996;93:4219-23.
32. Stallmach A, Schuppan D, Riese HH, Matthes H, Riecken EO. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology. 1992;102:1920-9.
33. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:172C-82C.
34. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol. 2003;162:1355-60.
35. Lawrance IC, Wu F, Leite AZ, Willis J, West GA, Fiocchi C, et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology. 2003;125:1750-61.
36. Vallance BA, Gunawan MI, Hewlett B, Bercik P, Van Kampen C, Galeazzi F, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol. 2005;289:116G-28G.
37. Wengrower D, Zannineli G, Pappo O, Latella G, Sestieri M, Villanova A, et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF-beta1. Inflamm Bowel Dis. 2004;10:536-45.
38. Theiss AL, Fuller CR, Simmons JG, Liu B, Sartor RB, Lund PK. Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology. 2005;129:204-19.